Antifungal resistance and susceptibility
Antifungal resistance and susceptibility is a research topic within Infectious Diseases. Science Explorer counts 43k research works in it since 1950. 16.5% of them reached the world's top 10% most cited for their field and year.
This cluster of papers covers the diagnosis, management, epidemiology, and treatment of various fungal infections such as candidiasis, aspergillosis, mucormycosis, and biofilm-related infections. It also discusses antifungal therapy, resistance mechanisms, and the impact of these infections on immunocompromised patients.
- Invasive Fungal Infections
- Candidiasis
- Aspergillosis
- Antifungal Therapy
- Mucormycosis
- Biofilm Formation
- Antifungal Resistance
- Epidemiology
- Immunocompromised Patients
- Diagnostic Methods
- Research works
- 43k fractional, since 1950
- In the world top 10%
- 7.1k per year above
- Top-10% rate
- 16.5% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +33% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Antifungal resistance and susceptibility research?
By volume, the United States and India publish the most (1.5k and 1.2k works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.5k works
- 2 India 1.2k works
- 3 China 946 works
- 4 Brazil 450 works
- 5 Japan 272 works
- 6 United Kingdom 246 works
- 7 Spain 219 works
- 8 Iran 213 works
- 9 France 203 works
- 10 Italy 170 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Antifungal resistance and susceptibility research?
By volume in 2022–2025, Post Graduate Institute of Medical Education and Research publishes the most Antifungal resistance and susceptibility research, followed by All India Institute of Medical Sciences and Universidade de São Paulo.
By volume, 2022–2025
- 1 Post Graduate Institute of Medical Education and ResearchIndia 59 works
- 2 All India Institute of Medical SciencesIndia 49 works
- 3 Universidade de São PauloBrazil 28 works
- 4 Universidade Estadual Paulista (Unesp)Brazil 24 works
- 5 University of ExeterUnited Kingdom 21 works
- 6 Institute of Medical SciencesIndia 20 works
- 7 Universidade Federal do Rio de JaneiroBrazil 19 works
- 8 Fundação Oswaldo CruzBrazil 19 works
- 9 Tehran University of Medical SciencesIran 18 works
- 10 University of ManchesterUnited Kingdom 18 works
Who are the leading researchers in Antifungal resistance and susceptibility?
The most-cited researchers publishing on Antifungal resistance and susceptibility include Peter C Gøtzsche and Roderick J. Hay.
- 1 Peter C Gøtzsche Denmark 6.7k citations
- 2 Roderick J. Hay United Kingdom 4k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Antifungal resistance and susceptibility research done?
The largest centres of Antifungal resistance and susceptibility research in 2022–2025 are New Delhi (India), Beijing (China), São Paulo (Brazil) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Jena, Raipur and Chandigarh.
Largest cities, 2022–2025
Where it is the local speciality
- JenaDE · 26.8 works8.4×
- RaipurIN · 30.3 works8.1×
- ChandigarhIN · 65.3 works8.0×
Location quotient: how much more of its research is in Antifungal resistance and susceptibility than the world average.
Where is the best place to study Antifungal resistance and susceptibility?
Among universities, judged by research, Universidad de Guanajuato, Post Graduate Institute of Medical Education and Research and University of Exeter score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Universidad de GuanajuatoMexico | 75.3 | 55.4% | 10.1× | 11 | +304.9% |
| 2 | Post Graduate Institute of Medical Education and ResearchIndia | 62.6 | 15.9% | 24.0× | 59 | +90.0% |
| 3 | University of ExeterUnited Kingdom | 61.0 | 45.8% | 6.7× | 21 | +38.5% |
| 4 | All India Institute of Medical SciencesIndia | 53.8 | 4.4% | 10.7× | 49 | +78.5% |
| 5 | Innsbruck Medical UniversityAustria | 53.0 | 33.3% | 15.9× | 11 | -20.2% |
| 6 | Medical University of GrazAustria | 51.8 | 30.5% | 11.1× | 10 | -9.3% |
| 7 | The University of Texas at San Antonio Health Science CenterUnited States | 51.2 | 34.1% | 10.0× | 11 | -7.3% |
| 8 | Mazandaran University of Medical SciencesIran | 50.7 | 10.3% | 18.8× | 13 | +182.9% |
| 9 | Institute of Medical SciencesIndia | 46.7 | 4.6% | 8.3× | 20 | +169.9% |
| 10 | Friedrich Schiller University JenaGermany | 44.6 | 38.7% | 6.3× | 10 | -3.4% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Antifungal resistance and susceptibility research growing?
Output in 2018–2022 was 33% higher than in 2013–2017, peaking in 2022. The fastest-growing topics are Antifungal resistance and susceptibility.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.